帕博利珠单抗单药治疗经治晚期胃癌及胃食管结合部癌的2期KEYNOTE-059试验安全性与疗效
该2期单臂多队列研究纳入259例经至少2线治疗失败的晚期胃癌或胃食管结合部癌患者,接受帕博利珠单抗200 mg每3周一次治疗。总客观缓解率为11.6%,PD-L1阳性患者为15.5%,PD-L1阴性患者为6.4%,耐受性可控。
要点
- 经≥2线治疗后晚期胃癌患者,帕博利珠单抗单药客观缓解率11.6%,完全缓解率2.3%。
- PD-L1阳性者客观缓解率15.5%,中位缓解持续时间16.3个月;PD-L1阴性者分别为6.4%和6.9个月。
- 17.8%患者发生≥3级治疗相关不良事件,2例(0.8%)因不良事件停药,2例死亡判定与治疗相关。
核心结论
- 帕博利珠单抗单药在既往接受至少2线治疗的晚期胃癌或胃食管结合部癌患者中显示出有前景的抗肿瘤活性和可控的安全性。
- PD-L1阳性与PD-L1阴性肿瘤患者中均观察到持久缓解。
研究设计与样本
- 2期、全球、开放标签、单臂、多队列KEYNOTE-059研究,共纳入16个国家259例患者。
- 入组时间为2015年3月2日至2016年5月26日,中位随访5.8个月(范围0.5-21.6个月)。
- 干预为帕博利珠单抗200 mg静脉注射每3周一次,直至疾病进展、研究者或患者决定退出或出现不可接受毒性。
主要发现
- 全部259例患者客观缓解率为11.6%(95% CI 8.0%-16.1%),完全缓解率2.3%(95% CI 0.9%-5.0%)。
- 中位缓解持续时间为8.4个月(范围1.6+至17.3+个月)。
- PD-L1阳性患者(148例)客观缓解率15.5%(95% CI 10.1%-22.4%),中位缓解持续时间16.3个月(范围1.6+至17.3+个月)。
- PD-L1阴性患者(109例)客观缓解率6.4%(95% CI 2.6%-12.8%),中位缓解持续时间6.9个月(范围2.4至7.0+个月)。
关键数值与推荐
- 客观缓解率由中心影像学评审按RECIST v1.1评估。
- PD-L1表达采用免疫组织化学法评估。
临床怎么用
- 对于既往至少2线治疗失败的晚期胃癌或胃食管结合部癌患者,帕博利珠单抗单药可作为考虑选项之一,需注意PD-L1状态与缓解概率的关系。
- 治疗期间需监测3-5级治疗相关不良事件,多数患者可耐受,少数需停药。
局限性
- 本研究为单臂2期试验,未设对照组,样本量有限,中位随访时间较短(5.8个月)。
- PD-L1阳性与阴性亚组的客观缓解率置信区间较宽,需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Therapeutic options are needed for patients with advanced gastric cancer whose disease has progressed after 2 or more lines of therapy. OBJECTIVE: To evaluate the safety and efficacy of pembrolizumab in a cohort of patients with previously treated gastric or gastroesophageal junction cancer. DESIGN, SETTING, AND PARTICIPANTS: In the phase 2, global, open-label, single-arm, multicohort KEYNOTE-059 study, 259 patients in 16 countries were enrolled in a cohort between March 2, 2015, and May 26, 2016. Median (range) follow-up was 5.8 (0.5-21.6) months. INTERVENTION: Patients received pembrolizumab, 200 mg, intravenously every 3 weeks until disease progression, investigator or patient decision to withdraw, or unacceptable toxic effects. MAIN OUTCOMES AND MEASURES: Primary end points were objective response rate and safety. Objective response rate was assessed by central radiologic review per Response Evaluation Criteria in Solid Tumors, version 1.1, in all patients and those with programmed cell death 1 ligand 1 (PD-L1)-positive tumors. Expression of PD-L1 was assessed by immunohistochemistry. Secondary end points included response duration. RESULTS: Of 259 patients enrolled, most were male (198 [76.4%]) and white (200 [77.2%]); median (range) age was 62 (24-89) years. Objective response rate was 11.6% (95% CI, 8.0%-16.1%; 30 of 259 patients), with complete response in 2.3% (95% CI, 0.9%-5.0%; 6 of 259 patients). Median (range) response duration was 8.4 (1.6+ to 17.3+) months (+ indicates that patients had no progressive disease at their last assessment). Objective response rate and median (range) response duration were 15.5% (95% CI, 10.1%-22.4%; 23 of 148 patients) and 16.3 (1.6+ to 17.3+) months and 6.4% (95% CI, 2.6%-12.8%; 7 of 109 patients) and 6.9 (2.4 to 7.0+) months in patients with PD-L1-positive and PD-L1-negative tumors, respectively. Forty-six patients (17.8%) experienced 1 or more grade 3 to 5 treatment-related adverse events. Two patients (0.8%) discontinued because of treatment-related adverse events, and 2 deaths were considered related to treatment. CONCLUSIONS AND RELEVANCE: Pembrolizumab monotherapy demonstrated promising activity and manageable safety in patients with advanced gastric or gastroesophageal junction cancer who had previously received at least 2 lines of treatment. Durable responses were observed in patients with PD-L1-positive and PD-L1-negative tumors. Further study of pembrolizumab for this group of patients is warranted. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02335411.
引用
- Fuchs CS, Doi T, Jang RW, et al. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol. 2018. PMID: 29543932. doi:10.1001/jamaoncol.2018.0013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。